18
Participants
Start Date
April 25, 2013
Primary Completion Date
October 3, 2018
Study Completion Date
October 3, 2018
Carfilzomib
"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I."
Lenalidomide
Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
Rituximab
Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (2)
Celgene
INDUSTRY
Onyx Therapeutics, Inc.
INDUSTRY
M.D. Anderson Cancer Center
OTHER